Table 4.
Relative risk of stroke and change in total cholesterol and triglyceride concentration between fibrates and placebo therapy
| Source | Triglyceride lowering | Total cholesterol lowering | Relative risk (RR) and 95% CI for stroke | Relative risk (RR) and 95% CI for fatal stroke |
|---|---|---|---|---|
| BIP study [8] (2000) |
11.0% |
3.0% |
0.93 (0.68, 1.27) |
- |
| VA-HIT study [10] (1999) |
31.0% |
4.0% |
0.73 (0.53, 1.00) |
0.33 (0.09, 1.23) |
| Acheson J [17] (1972) |
NR |
6.4% |
1.07 (0.70, 1.63) |
0.41 (0.08, 2.00) |
| Veterans Administration Cooperative Study Group [18] (1973) |
33.2% |
3.7% |
1.58 (0.97, 2.59) |
0.70 (0.23, 2.19) |
| Coronary Drug Project Research Group [19] (1975) |
22.3% |
6.5% |
1.11 (0.92, 1.34) |
- |
| WHO-COOP committee of principal Investigators [20] (1978) |
NR |
9.0% |
1.18 (0.71, 1.96) |
0.99 (0.47, 2.08) |
| LEADER study [21,22] (2002) |
23.4% |
8.1% |
1.23 (0.85, 1.77) |
1.45 (0.62, 3.37) |
| E J Whitney [23] (2005) |
21.5% |
6.8% |
0.90 (0.73, 1.12) |
- |
| FIELD study [24] (2005) |
49.8% |
19.6% |
0.20 (0.01, 4.15) |
- |
| The ACCORD Study Group [25] (2010) | 15.6% | NR | 1.06 (0.72, 1.56) | 0.50 (0.15, 1.65) |